Workflow
Knight Therapeutics Reports First Quarter 2025 Results
GlobeNewswire·2025-05-08 11:30

Financial Results - Revenues for Q1-25 were 88,076,anincreaseof88,076, an increase of 1,472 or 2% compared to Q1-24, driven by growth in key promoted products, partially offset by declines in mature products and currency depreciation in select LATAM countries [7][13] - Gross margin decreased to 34,866or4034,866 or 40% of revenues from 41,699 or 48% in the same period last year, primarily due to hyperinflation accounting in Argentina [7][19] - Operating loss was 5,537comparedtoanoperatingincomeof5,537 compared to an operating income of 2,660 in Q1-24 [11][25] - Net income was 2,185,asignificantimprovementfromanetlossof2,185, a significant improvement from a net loss of 4,546 in the prior year [25] - Adjusted revenues were 87,979,reflectinga387,979, reflecting a 3% increase, and 6,631 or 8% on a constant currency basis [7][13] Corporate Developments - The company entered into an asset purchase agreement to acquire the Paladin business for 100,000,withanadditional100,000, with an additional 20,000 for inventory, and potential future payments of up to 15,000basedonsalesmilestones[7][36]AworkingcapitallineofcreditofUSD40,000wasobtainedfromCitibank,withUSD35,000withdrawn[6][37]ThecompanyinlicensedOnicitIVfordistributioninMexico,Brazil,andselectLATAMcountries,andsubmittedTavalisseforANMATapprovalinArgentina[8][33][35]ShareholderUpdatesShareholdersreelectedmemberstotheBoardofDirectors,includingJonathanRossGoodmanandSamiraSakhia[9]FinancialOutlookThecompanyreaffirmeditsfinancialguidancefor2025,expectingrevenuesbetween15,000 based on sales milestones [7][36] - A working capital line of credit of USD 40,000 was obtained from Citibank, with USD 35,000 withdrawn [6][37] - The company in-licensed Onicit IV for distribution in Mexico, Brazil, and select LATAM countries, and submitted Tavalisse for ANMAT approval in Argentina [8][33][35] Shareholder Updates - Shareholders re-elected members to the Board of Directors, including Jonathan Ross Goodman and Samira Sakhia [9] Financial Outlook - The company reaffirmed its financial guidance for 2025, expecting revenues between 390 million to $405 million and adjusted EBITDA to be approximately 13% of revenues [38]